Open AccessDevelopment and in vivo Evaluation of Nelfinavir Extended Release Trilayer Matrix Tablets in the Management of AIDS
Author(s) -
Rangu Nirmala,
Suresh Gorle
Publication year - 2018
Publication title -
international journal of pharmaceutical sciences and drug research
Language(s) - English
Resource type - Journals
ISSN - 0975-248X
DOI - 10.25004/ijpsdr.2018.100421
Subject(s) - microcrystalline cellulose , bioavailability , pharmaceutics , magnesium stearate , nelfinavir , materials science , matrix (chemical analysis) , drug delivery , xanthan gum , dissolution , chromatography , drug , in vivo , dissolution testing , dosage form , pharmacology , chemistry , cellulose , nanotechnology , composite material , organic chemistry , medicine , microbiology and biotechnology , family medicine , antiretroviral therapy , rheology , viral load , biology , human immunodeficiency virus (hiv) , biopharmaceutics classification system
The purpose of this investigation was to design and develop trilayer matrix tablets of Nelfinavir prepared bydirect compression method and consisted of middle active layer with different grades of hydroxypropylmethylcellulose (HPMC), PVK K 30 and MCC. Barrier layers are prepared with Polyox WSR 303, Xanthan gum,microcrystalline cellulose and magnesium stearate. Based on the evaluation parameters, drug dissolution profileand release drug kinetics DF8 was found to be optimized formulation. The developed drug delivery systemprovided prolonged drug release rates over a period of 24 h. The release profile of the optimized formulation(DF8) was described by the Zero-order and best fitted to Higuchi model. From in vivo bioavailability studies theextended release of Nelfinavir from trilayer matrix tablets also provides for higher plasma drug content andimproved bioavailability. The results indicate that the approach used could lead to a successful development oflow biological half life Nelfinavir with controlled drug release in the effective management of AIDS.